文献速递肝病消化道肿瘤与早癌

原发与复发性肝细胞癌的基因组与表观基因组特征

Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
PubMed 文献 · Gastroenterology · 2019-09-24

该研究对113例接受部分肝切除术的原发或复发肝细胞癌患者的356份肿瘤标本进行全基因组、全外显子或靶向捕获测序,并对95份标本进行DNA甲基化分析。研究发现52%的复发肝细胞癌源自初始肿瘤的克隆谱系,肝硬化组织存在易化肿瘤发生的甲基化场效应,并鉴定出TP53 R249S突变通过调控MLL1/MLL2及JAK-STAT通路促进肿瘤进展,相应抑制剂可特异性抑制表达该突变的肝癌细胞增殖。

要点

  • 52%的复发肝细胞癌来自初始肿瘤的克隆谱系。
  • 肝硬化肝组织DNA甲基化场效应可提示肿瘤发生风险。
  • TP53 R249S突变上调染色质调控因子MLL1/MLL2,MLL复合物拮抗剂可抑制此类细胞增殖。

核心结论

  • 肝细胞癌的基因组与表观基因组特征存在相互作用和共依赖,与肿瘤进展和复发相关。
  • 肝硬化或纤维化肝组织的DNA甲基化模式或可用于识别肝细胞癌发生风险。
  • 突变型TP53上调的染色质调控因子及其抑制剂为肝癌治疗提供潜在靶点。

研究设计与样本

  • 收集113例因原发或复发肝细胞癌接受部分肝切除术患者的肿瘤及配对非肿瘤肝标本。
  • 对356份来自多个肿瘤区域及配对初发和复发肿瘤的肝细胞癌标本进行全基因组、全外显子或靶向捕获测序。
  • 对95份标本进行平行DNA甲基化谱分析,并分析含肝硬化或纤维化区域的非肿瘤组织基因组和表观基因组。
  • 构建内源性表达TP53 R249S突变或过表达STAT3、JAK1突变体的肝癌细胞系,测试药物降低活性的能力。

主要发现

  • 采用单样本采集方法可捕获肿瘤所有区域检测到的90%以上突变,并确定单个肿瘤的单克隆起源。
  • 系统发育和系统表观遗传学分析揭示肝细胞癌基因组与表观基因组特征间的相互作用和共依赖。
  • 甲基化分析显示肝硬化肝组织存在易化肿瘤发生的场效应。
  • 52%的复发肝细胞癌源自初始肿瘤的克隆谱系,据此可构建与肿瘤复发相关的遗传改变时间图。
  • JAK-STAT信号激活是肝细胞癌进展的特征,与药物敏感性反应相关的突变有关。

关键数值与推荐

  • 52%的复发肝细胞癌源自初始肿瘤的克隆谱系。
  • 单样本采集方法捕获肿瘤所有区域检测到的90%以上突变。
  • TP53 R249S突变与编码染色质调控因子MLL1和MLL2的基因相互作用,二者为TP53R249S的直接靶点,并在癌症基因组图谱数据集中得到验证。
  • MLL复合物拮抗剂MI-2-2和OICR-9492在纳摩尔浓度下特异性抑制表达TP53R249S的肝细胞癌细胞增殖。

临床怎么用

  • 对肝硬化或纤维化肝组织进行DNA甲基化分析或有助于识别肝细胞癌发生高风险个体。
  • 复发肝细胞癌的克隆起源分析可为构建肿瘤复发相关遗传改变时间图提供依据。
  • 携带TP53 R249S突变的肝细胞癌或可考虑MLL复合物拮抗剂作为潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Intratumor heterogeneity and divergent clonal lineages within and among primary and recurrent hepatocellular carcinomas (HCCs) produce challenges to patient management. We investigated genetic and epigenetic variations within liver tumors, among hepatic lesions, and between primary and relapsing tumors. METHODS: Tumor and matched nontumor liver specimens were collected from 113 patients who underwent partial hepatectomy for primary or recurrent HCC at 2 hospitals in Hong Kong. We performed whole-genome, whole-exome, or targeted capture sequencing analyses of 356 HCC specimens collected from multiple tumor regions and matched initial and recurrent tumors. We performed parallel DNA methylation profiling analyses of 95 specimens. Genomes and epigenomes of nontumor tissues that contained areas of cirrhosis or fibrosis were analyzed. We developed liver cancer cell lines that endogenously expressed a mutant form of TP53 (R249S) or overexpressed mutant forms of STAT3 (D170Y, K348E, and Y640F) or JAK1 (S703I and L910P) and tested the abilities of pharmacologic agents to reduce activity. Cells were analyzed by immunoblotting and chromatin immunoprecipitation with quantitative polymerase chain reaction. RESULTS: We determined the monoclonal origins of individual tumors using a single sample collection approach that captured more than 90% of mutations that are detected in all regions of tumors. Phylogenetic and phylo-epigenetic analyses revealed interactions and codependence between the genomic and epigenomic features of HCCs. Methylation analysis revealed a field effect in cirrhotic liver tissues that predisposes them to tumor development. Comparisons of genetic features revealed that 52% of recurrent HCCs derive from the clonal lineage of the initial tumor. The clonal origin if recurrent HCCs allowed construction of a temporal map of genetic alterations that associated with tumor recurrence. Activation of JAK signaling to STAT was a characteristic of HCC progression via mutations that associate with response to drug sensitivity. The combination of a mutation that increases the function of TP53 and the 17p chromosome deletion might provide liver cancer cells with a replicative advantage. Chromatin immunoprecipitation analysis of TP53 with the R249S substitution revealed its interaction with genes that encode chromatin regulators (MLL1 and MLL2). We validated MLL1 and MLL2 as direct targets of TP53R249S and affirmed their association in the Cancer Genome Atlas dataset. The MLL-complex antagonists MI-2-2 (inhibitor of protein interaction) and OICR-9492 (inhibitor of activity) specifically inhibited proliferation of HCC cells that express TP53R249S at nanomolar concentrations. CONCLUSIONS: We performed a systematic evaluation of intra- and intertumor genetic heterogeneity in HCC samples and identified genetic and epigenetic changes that associate with tumor progression and recurrence. We identified chromatin regulators that are upregulated by mutant TP53 in HCC cells and inhibitors that reduce proliferation of these cells. DNA methylation patterns in cirrhotic or fibrotic liver tissues might be used to identify those at risk of HCC development.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ding X, He M, Chan AWH, et al. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. Gastroenterology. 2019. PMID: 31560893. doi:10.1053/j.gastro.2019.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。